ANI Pharmaceuticals (NASDAQ:ANIP) Earns “Buy” Rating from Guggenheim

ANI Pharmaceuticals (NASDAQ:ANIP)‘s stock had its “buy” rating restated by equities research analysts at Guggenheim in a research note issued on Tuesday, Benzinga reports. They presently have a $77.00 price objective on the specialty pharmaceutical company’s stock. Guggenheim’s price objective points to a potential upside of 17.68% from the stock’s current price.

ANIP has been the subject of several other reports. HC Wainwright increased their price objective on ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a “buy” rating in a report on Monday, March 4th. Truist Financial increased their price objective on ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Finally, Capital One Financial initiated coverage on ANI Pharmaceuticals in a report on Friday, March 15th. They set an “overweight” rating and a $80.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average price target of $80.00.

ANI Pharmaceuticals Stock Performance

ANIP opened at $65.43 on Tuesday. The firm has a market cap of $1.38 billion, a PE ratio of 77.94 and a beta of 0.79. The company has a quick ratio of 2.81, a current ratio of 3.57 and a debt-to-equity ratio of 0.66. The business has a fifty day simple moving average of $65.34 and a 200-day simple moving average of $58.75. ANI Pharmaceuticals has a fifty-two week low of $36.99 and a fifty-two week high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $131.65 million during the quarter, compared to analysts’ expectations of $123.02 million. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. As a group, equities analysts predict that ANI Pharmaceuticals will post 3.55 EPS for the current fiscal year.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Chad Gassert sold 20,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $67.25, for a total transaction of $1,345,000.00. Following the transaction, the senior vice president now directly owns 253,226 shares in the company, valued at $17,029,448.50. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, CEO Nikhil Lalwani sold 28,965 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $65.52, for a total value of $1,897,786.80. Following the transaction, the chief executive officer now directly owns 444,981 shares in the company, valued at $29,155,155.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $67.25, for a total value of $1,345,000.00. Following the completion of the transaction, the senior vice president now owns 253,226 shares in the company, valued at $17,029,448.50. The disclosure for this sale can be found here. Insiders have sold a total of 156,803 shares of company stock worth $10,363,466 over the last three months. Corporate insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in shares of ANI Pharmaceuticals by 5.4% in the third quarter. Vanguard Group Inc. now owns 1,132,378 shares of the specialty pharmaceutical company’s stock worth $65,746,000 after purchasing an additional 58,204 shares during the period. Rubric Capital Management LP increased its stake in shares of ANI Pharmaceuticals by 32.8% in the fourth quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock worth $62,032,000 after purchasing an additional 277,989 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of ANI Pharmaceuticals by 6.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 591,731 shares of the specialty pharmaceutical company’s stock worth $32,628,000 after purchasing an additional 33,359 shares during the period. Global Alpha Capital Management Ltd. increased its stake in shares of ANI Pharmaceuticals by 10.8% in the fourth quarter. Global Alpha Capital Management Ltd. now owns 582,428 shares of the specialty pharmaceutical company’s stock worth $32,115,000 after purchasing an additional 56,900 shares during the period. Finally, Ranger Investment Management L.P. increased its stake in shares of ANI Pharmaceuticals by 1.8% in the fourth quarter. Ranger Investment Management L.P. now owns 434,617 shares of the specialty pharmaceutical company’s stock worth $23,965,000 after purchasing an additional 7,769 shares during the period. 76.05% of the stock is currently owned by institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.